跻身创新药“一线城市”后，成都如何再进一步？

Core Viewpoint - Chengdu's biopharmaceutical industry is experiencing rapid growth, positioning itself as a leading hub for innovation in the sector, prompting discussions on how to capitalize on this momentum and attract more high-caliber pharmaceutical companies [1][2]. Group 1: Industry Growth and Opportunities - The biopharmaceutical sector is witnessing an explosion of high-growth sub-sectors, with potential areas for development including nuclear medicine, where Chengdu has existing advantages and emerging representative companies [2][3]. - The integration of AI with biopharmaceuticals is seen as a potential avenue for disruptive innovation, with local resources in both AI and pharmaceuticals being leveraged to explore this intersection [2][3]. Group 2: Medical Device Sector Development - Chengdu is addressing its shortcomings in the medical device sector, with the establishment of a comprehensive service platform for medical devices and CDMO projects, which will enhance local testing capabilities [3]. - The medical device industry in China has significant growth potential, with a current "drug-device ratio" of 4:1 compared to 1:1 in Western countries, indicating room for expansion [3]. Group 3: Ecosystem and Structural Challenges - Chengdu's pharmaceutical ecosystem is nearly complete but lacks a top-tier production base among the national top 500 companies, which is essential for a full industrial chain [4]. - There are calls for a more robust ecosystem that supports continuous innovation in pharmaceuticals, emphasizing the need for systemic reforms to facilitate the establishment of international pharmaceutical companies [5][6]. Group 4: Policy and Regulatory Environment - The efficiency of regulatory processes is crucial for attracting pharmaceutical companies, as seen in the example of a large pharmaceutical firm choosing Suzhou due to streamlined customs processes [6]. - Improving policy details and regulatory frameworks could enable Chengdu to attract key enterprises more rapidly than other cities, enhancing its competitive edge in the biopharmaceutical landscape [6].